Question 1

How many shares of MLTX does BALYASNY ASSET MANAGEMENT L.P. own?

Accepted Answer

As of 2026-Q2, BALYASNY ASSET MANAGEMENT L.P. holds 912,715 shares of MLTX (MoonLake Immunotherapeutics Class A).

Question 2

What is BALYASNY ASSET MANAGEMENT L.P.'s MLTX position worth?

Accepted Answer

As of 2026-Q2, BALYASNY ASSET MANAGEMENT L.P.'s MLTX position is worth $17.8M.

Question 3

Is BALYASNY ASSET MANAGEMENT L.P. buying or selling MLTX?

Accepted Answer

In 2026-Q2, BALYASNY ASSET MANAGEMENT L.P. decreased their MLTX position (-14.3% change in shares).

Question 4

When did BALYASNY ASSET MANAGEMENT L.P. first buy MLTX?

Accepted Answer

Based on available 13F filings, BALYASNY ASSET MANAGEMENT L.P. first reported a position in MLTX in 2024-Q3. They have held the position across 16 quarters.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	912,715	-14.3%	$17.8M	0.0%	$19.47	0
2026-Q1	Decreased	1.1M	-32.2%	$19.9M	0.0%	$17.69	0
2025-Q4	Decreased	1.6M	-7.5%	$20.7M	0.0%	$13.21	0
2025-Q3	Increased	1.7M	+301.6%	$12.2M	0.0%	$6.24	45
2025-Q2	Increased	423,170	+436.8%	$20M	0.0%	$47.52	46
2025-Q1	Decreased	78,835	-61.8%	$3.1M	0.0%	$39.86	0
2024-Q4	Decreased	206,568	-42.6%	$11.2M	0.0%	$53.02	0
2024-Q3	Decreased	360,200	-38.4%	$18.2M	0.0%	$49.40	0